Clinical trial
A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With…
NCT00207025 · Bristol-Myers Squibb, Industry · Terminated
Key facts
| NCT number | NCT00207025 |
|---|---|
| Title | A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies |
| Official title | A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Tumors |
| Intervention type | Drug |
| Interventions | BMS-275183 |
| Enrollment | 60 |
| Start date | Oct 1, 2004 |
| Primary completion | Feb 1, 2007 |
| First posted | Sep 21, 2005 |
| Last update posted | Mar 2, 2010 |
| Countries | Belgium, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: